A phase 2 study to evaluate the efficacy and safety of Trastuzumab Deruxtecan for molecular progression based on ctDNA analysis during CDK4/6 inhibitor and endocrine treatment in patients with HR-positive and HER2-low metastatic breast cancer (JBCRG-M11 ( CAERUS trial ) )

未提供0 个研究点目标入组 110 人开始时间: 待定

适应症

试验速览

阶段: 不适用
状态: 招募中
入组人数: 110

研究概览研究设计入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional
分配方式: Single Arm Study

入排标准

年龄范围: 18age old over 至 No limit（—）
性别: Female

入选标准

•Performance status is 0 or 1 according to the ECOG criteria.
•Estrogen receptor positive or progesterone receptor positive breast cancer has been confirmed.
•HER2 low status has been confirmed by an approved companion diagnostic test.
•Prior to initiation of therapy with a CDK4 and 6 inhibitor in combination with endocrine therapy, the presence of distant metastatic disease meeting at least one of the following criteria has been confirmed. This corresponds to metastatic breast cancer. Visceral metastasis. Two or more lymph node metastases. Two or more bone metastases. Patients are eligible if the above metastatic lesions were confirmed by imaging before initiation of therapy with a CDK4 and 6 inhibitor in combination with endocrine therapy, even if the lesions are no longer detectable at the time of primary registration due to treatment response.
•The patient is currently receiving therapy with a CDK4 and 6 inhibitor in combination with endocrine therapy as first line treatment or second line treatment for metastatic breast cancer. Definitions of eligible first line and second line therapies are as follows.
•a. De novo Stage IV breast cancer. First line therapy is defined as the first systemic drug therapy initiated. Second line therapy is defined as the second systemic drug therapy initiated after endocrine monotherapy was used as the first systemic therapy.
•b. Recurrence during or within 12 months after completion of adjuvant endocrine therapy. First line therapy is not applicable. Second line therapy is defined as the first systemic drug therapy after recurrence.
•c. Recurrence occurring 12 months or more after completion of adjuvant endocrine therapy. First line therapy is defined as the first systemic drug therapy after recurrence. Second line therapy is defined as the second systemic drug therapy initiated after endocrine monotherapy was used as the first systemic therapy after recurrence.
•Therapy with a CDK4 and 6 inhibitor in combination with endocrine therapy has been continued without disease progression for at least 3 months and less than 15 months, and all of the following conditions are met.
•a. The CDK4 and 6 inhibitor is abemaciclib or palbociclib. If abemaciclib or palbociclib was administered as perioperative therapy, at least 12 months must have elapsed between the last dose and disease recurrence.
•b. The endocrine therapy is either an aromatase inhibitor, including anastrozole or letrozole, or fulvestrant, and must be an agent for which resistance has not previously been confirmed. Resistance is defined as recurrence during perioperative therapy or within 12 months after the last dose, or disease progression during treatment for metastatic breast cancer. Premenopausal patients must additionally receive a luteinizing hormone releasing hormone agonist.
•c. All study drugs are administered in accordance with the approved dosage and administration described in the package insert.
•The patient has not received cytotoxic chemotherapy for the treatment of metastatic breast cancer. Molecular targeted agents and endocrine therapy are excluded.

排除标准

•The patient has central nervous system metastases, regardless of whether the metastases are active or inactive.
•The patient has multiple primary malignancies.
•The patient has myocardial infarction or symptomatic congestive heart failure classified as New York Heart Association Class II to Class IV, or has a history of any of these conditions within 6 months prior to primary registration.
•The patient has non infectious interstitial lung disease or pneumonitis requiring steroid treatment, or has a history of these conditions.
•The patient is pregnant, breastfeeding, or planning to become pregnant.

研究者

发起方

未提供

相似试验

招募中

1 期

A Phase I study to evaluate the safety and efficacy of L19IL2 in combination with ruxolitinib in patients with advanced solid tumors.

2025-522243-17-00Philogen S.p.A.96

招募中

1 期

An early Phase 1b Study to assess how safe and effective is the treatment with drugs, called Mosunetuzumab or Glofitamab in Combination with drugs called, CC-220 and CC-99282 in Patients with B-Cell Non-Hodgkin Lymphoma.

2023-505185-28-00F. Hoffmann-La Roche AG52

招募中

2 期

A study to evaluate the safety and efficacy of the tumor-targeting human antibody-cytokine fusion protein L19TNF plus lomustine in patients with glioblastoma at first progressionGlioblastoma

2022-501822-39-00Philogen S.p.A.113

招募中

不适用

Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease (J2A-MC-GZPR)Peripheral Arterial Disease

jRCT20312505701,205

招募中

1 期

A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants with Advanced Solid Malignancies

2024-511453-22-00Kumquat Biosciences Inc.112